- Kidney Transplant Home
AlloSure® is the first and only clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.
The most comprehensive tool for transplant patient surveillance. KidneyCare™ combines clinically validated AlloSure test with research use only AlloMap® Kidney and KidneyCare™ iBox, enabling you to follow trends and trajectory of kidney allograft health.
Drive better outcomes for kidney transplant recipients
Better surveillance. Better outcomes.
AlloSure® is the first non-invasive test that assesses organ health by directly measuring allograft injury, enabling better management of your kidney transplant recipients.
What is AlloSure?
AlloSure is a clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury.
What is Cell-free DNA (cfDNA)?
AlloSure is validated and reimbursable through Medicare
It’s time for innovation
The latest innovation in kidney transplant surveillance.
The most comprehensive tool for transplant patient surveillance.*
What is KidneyCare?
KidneyCare™ is the most comprehensive option for surveilling kidney allograft health, combining our clinically-validated AlloSure® Kidney dd-cfDNA test, gene expression profiling with AlloMap® Kidney, and predictive intelligence with KidneyCare™ iBox.
The latest innovation in kidney transplant surveillance can drive better outcomes for your patients.
Graft survival prognosis
*KidneyCare is available for research use only and not intended for diagnostic procedures.